Teixobactin, the first of a new class of antibiotics discovered by iChip technology?

Research output: Contribution to journalArticlepeer-review

Standard

Teixobactin, the first of a new class of antibiotics discovered by iChip technology? / Piddock, Laura J V.

In: Journal of Antimicrobial Chemotherapy, Vol. 70, No. 10, 10.2015, p. 2679-80.

Research output: Contribution to journalArticlepeer-review

Harvard

APA

Vancouver

Author

Bibtex

@article{35c7c51a58ec432bbc00345b5ccc35e1,
title = "Teixobactin, the first of a new class of antibiotics discovered by iChip technology?",
abstract = "Teixobactin is a recently described antibiotic of a new class produced by a hitherto undescribed soil microorganism (provisionally named Eleftheria terrae). It was isolated with a new tool, the iChip, that allowed the environmental bacterium to grow and for the antibiotic it produced to be isolated and subsequently identified. Teixobactin has activity against Gram-positive (but not Gram-negative) organisms and mycobacteria and a novel mode of action inhibiting peptidoglycan biosynthesis. In vitro no teixobactin-resistant Staphylococcus aureus or Mycobacterium tuberculosis were selected. In experimental infections of MRSA and Streptococcus pneumoniae in mice, teixobactin was effective at reducing the bacterial load. Although teixobactin is at an early stage of development and there are no guarantees it will make it to market, the use of the iChip will hopefully result in the discovery of further potential new antibiotics.",
author = "Piddock, {Laura J V}",
note = "{\textcopyright} The Author 2015. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.",
year = "2015",
month = oct,
doi = "10.1093/jac/dkv175",
language = "English",
volume = "70",
pages = "2679--80",
journal = "Journal of Antimicrobial Chemotherapy",
issn = "0305-7453",
publisher = "Oxford University Press",
number = "10",

}

RIS

TY - JOUR

T1 - Teixobactin, the first of a new class of antibiotics discovered by iChip technology?

AU - Piddock, Laura J V

N1 - © The Author 2015. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

PY - 2015/10

Y1 - 2015/10

N2 - Teixobactin is a recently described antibiotic of a new class produced by a hitherto undescribed soil microorganism (provisionally named Eleftheria terrae). It was isolated with a new tool, the iChip, that allowed the environmental bacterium to grow and for the antibiotic it produced to be isolated and subsequently identified. Teixobactin has activity against Gram-positive (but not Gram-negative) organisms and mycobacteria and a novel mode of action inhibiting peptidoglycan biosynthesis. In vitro no teixobactin-resistant Staphylococcus aureus or Mycobacterium tuberculosis were selected. In experimental infections of MRSA and Streptococcus pneumoniae in mice, teixobactin was effective at reducing the bacterial load. Although teixobactin is at an early stage of development and there are no guarantees it will make it to market, the use of the iChip will hopefully result in the discovery of further potential new antibiotics.

AB - Teixobactin is a recently described antibiotic of a new class produced by a hitherto undescribed soil microorganism (provisionally named Eleftheria terrae). It was isolated with a new tool, the iChip, that allowed the environmental bacterium to grow and for the antibiotic it produced to be isolated and subsequently identified. Teixobactin has activity against Gram-positive (but not Gram-negative) organisms and mycobacteria and a novel mode of action inhibiting peptidoglycan biosynthesis. In vitro no teixobactin-resistant Staphylococcus aureus or Mycobacterium tuberculosis were selected. In experimental infections of MRSA and Streptococcus pneumoniae in mice, teixobactin was effective at reducing the bacterial load. Although teixobactin is at an early stage of development and there are no guarantees it will make it to market, the use of the iChip will hopefully result in the discovery of further potential new antibiotics.

U2 - 10.1093/jac/dkv175

DO - 10.1093/jac/dkv175

M3 - Article

C2 - 26089440

VL - 70

SP - 2679

EP - 2680

JO - Journal of Antimicrobial Chemotherapy

JF - Journal of Antimicrobial Chemotherapy

SN - 0305-7453

IS - 10

ER -